Subscribe to Blog via Email
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms.
Gastric neuroendocrine neoplasms (gNENs) are tumours with an increasing annual incidence and. The vast majority of gNENs are well-differentiated neuroendrocrine tumours (NETs), which are usually classified according to the background gastric pathology into three major categories known as “types” – these should not be confused with “grades” which are generated by histopathological tissue sampling (biopsy).
Type I when chronic atrophic gastritis (CAG) is present resulting in hypergastrinaemia (high Gastrin) and high gastric pH. They are the most common type, accounting for 75%–80% of all gNENs. Type I gNETs are normally ‘indolent’ with negligible risk of metastases (<5%) and excellent long-term survival (almost 100%).
Type II when the tumour occurs due to hypergastrinaemia (high Gastrin) but low gastric pH and in the context of Zollinger–Ellison syndrome (ZES) via a Gastrinoma. They most often associated with multiple endocrine neoplasia type I (MEN-I) syndrome. Sporadic Type II is rare. This type accounts for 5% of gNENs.
Type III, which are sporadic lesions not associated with hypergastrinaemia and with normal gastric pH (15%–25% of gNENs). Type III tumours are usually more aggressive, owing to the high prevalence of metastatic disease (>50%) and the more unfavourable long-term survival (5-year survival rate 70%), although they present well-differentiated morphology in the majority of cases. Type III gNENs may also have higher grades.
clinical questions for gNET scenarios.
(The reference document covers Gastric NETs (1-7) and Duodenal NETs (8-10))
|Q1 – What is the role of endoscopic resection for type I gNETs? Is additional treatment required in cases of R1 endoscopic resection?|
|Q2 – When should somatostatin analogues be used to treat type I gNETs?|
|Q3 – What is the recommended follow-up schedule in type I gNETs?|
|Q4 – When is surgery recommended for type I gNETs?|
|Q5 – Can endoscopic treatments be proposed to treat type III gNETs?|
|Q6 – When should limited or extended surgical treatments be proposed to treat type III gNETs?|
|Q7 – What scheduled follow-up is recommended after endoscopic/surgical resection of type III gNETs?|
Now read the reference material below including where applicable the Functional pancreatic NET syndromes related in some way to Type II gNETs
Click on the blue link below see read the discussion and the recommendations for each of those questions.
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
What is Carcinoid Syndrome? Carcinoid syndrome (CS) is the most frequent hormonal complication accompanying neuroendocrine neoplasms (NENs) and is defined by chronic diarrhoea and/or flushing in the
I was delighted to see this clinical trial which looks at the efficacy of PRRT (Lu177) vs the efficacy of Everolimus (Afinitor). The latter is
November is always busier as I help spread awareness for 10th Nov (remembering that every day is 10th Nov on my site!). I also managed
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for Digestive Neuroendocrine Carcinoma
This ENETS guidance paper, developed by a multidisciplinary working group, provides up-to-date and practical advice on the diagnosis and management of digestive neuroendocrine carcinoma, based
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastric neuroendocrine tumours (NETs) G1–G3
The ENETS 2023 guideline for gNETs are combined with the guidelines for Duodenal NET (dNET) due to their close relationship in anatomical terms. Gastric neuroendocrine
Subscribe to Blog via Email
A cup of tea
I would also mention those who contributed to my “Tea Fund” which resides on PayPal. You don’t need a PayPal account as you can select a card but don’t forget to select the number of units first (i.e. 1 = £4, 2 = £8, 3 = £12, and so on), plus further on, tick a button to NOT create a PayPal account if you don’t need one. Clearly, if you have a PayPal account, the process is much simpler
Through your generosity, I am able to keep my sites running and provide various services for you. I have some ideas for 2023 but they are not detailed enough to make announcements yet.
This screenshot is from every single post on my website and depending on which machine you are using, it will either be top right of the post or at the bottom (my posts are often long, so scroll down!)